Monoclonal antibody · Antagonist of epidermal growth factor receptor (EGFR) · developed by Amgen
Panitumumab is a fully human antibody that binds the epidermal growth factor receptor (EGFR) on normal and tumor cells and competitively blocks ligand binding, preventing receptor autophosphorylation and downstream signaling. It is studied in advanced solid tumors, and its labeled use is in metastatic colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 23, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07172919 | Phase 2 | Advanced Solid Tumors | Recruiting | AMGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid Tumors
Updated Nov 22, 2026. Something wrong or missing? Report it on the AMGN page.
See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AMGN catalysts and pipeline →